Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1215 | Dietary Intervention Wiki | 0.71 |
| drug1397 | Enoxaparin 1 mg/kg Wiki | 0.71 |
| drug4145 | Unfractionated Heparin IV Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.
Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVT
Measure: Primary endpoint: Venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlierDescription: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia
Measure: Key secondary endpoint: Clinically evident venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlierGeneral objective of the study To assess the efficacy and safety of enoxaparin in hospitalized patients with moderate to severe COVID-19 (Coronavirus Disease 2019) infection. Study Design The study consists of two parts: - a phase II single-arm interventional prospective study including all patients treated with the study drug; - an observational prospective cohort study including all patients screened for receiving the study drug but not included in the phase II study. Patients will be enrolled from "date of study approval" for 1 month. Each patient will be followed-up for a minimum of 90 days after COVID19 diagnosis.
Description: Rates of hospitalized patients dead for all-cause within 30 days and 90 days from the first LMWH subcutaneous injection
Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19. Time: 30 days and 90 days from the first LMWH subcutaneous injectionDescription: Based on the four levels scale of severity of symptoms. Any change from one level to another will be detected for all the enrolled patients, in order to evalutate the clinical efficacy of enoxaparin on the outcome of COVID 19.
Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19. Time: This evaluation will be performed at 30 days and 90 days from the first LMWH subcutaneous injectionDescription: Evolution of the clinical severity during treatment, based on the number and rate of patients admitted to ICU and the length of their ICU stay
Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19. Time: This evaluation will be performed at 14 days (the last day of treatment adminstration), at 30 days and 90 days from the first LMWH subcutaneous injectionDescription: Difference between groups in number of days of hospitalization from admission to discharge
Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19. Time: This evaluation will be performed at 90 days from admissionDescription: Rate of adverse events (AEs) during treatment, at the end of treatment (EOT) and at 30 days after EOT. • Severity of AEs classified according to common terminology criteria for adverse events (CTCAE). The worst degree ever suffered will be considered.
Measure: To analyse the safety of enoxaparin in hospitalized patients with moderatesevere COVID-19. Time: 45 daysDescription: Occurrence of thromboembolic event at 90 days after COVID-19 diagnosis. Description of the type, distribution and severity of thromboembolic events.
Measure: To describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of COVID-19. Time: 90 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports